Introducing: Petrelintide Discover the Promise of Amylin Agonist Medications for Weight Loss Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Eloralintide vs #Cagrilintide Amylin based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! Eloralintide, a selective amylin receptor agonist Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial https: t.co H1Kb3FKp3j Everyone and their mother is talking about eloralintide, the new amylin receptor agonist showing up to 20% body weight reduction in early trials. Gabriel Alizaidy, MD, MS